Description: Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its product platform is Photodisinfection, a light-based antimicrobial technology that provides destruction of pathogens without causing antibiotic resistance. The company's lead product is Steriwave, a nasal photodisinfection solutions that destroys bacteria, viruses, and fungi colonizing the nose which leads to healthcare-associated infections. Its product pipeline also includes the development of topical antiviral therapy for the upper respiratory tract to reduce SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.
Home Page: ondinebio.com
1100 Melville Street
Vancouver,
BC
V6E 4A6
Canada
Phone:
604 669 0555
Officers
| Name | Title |
|---|---|
| Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA | Founder, CEO & Executive Director |
| Dr. Nicolas G. Loebel Ph.D. | President, CTO & Executive Director |
| Mr. Kwong Choo CPA, CIMA | Interim Chief Financial Officer |
| Mr. William Kanz | Senior VP of Engineering & Operations |
| Ms. Angelika Vance | Vice President of Corporate Communications |
| Mr. Matt Ross | Vice President of Sales & Marketing |
| Ms. Elaine Lei CPA | Corporate Controller |
| Mr. Nikita Parkev | VP of Finance & Company Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2280.9656 |
| Price-to-Sales TTM: | 24.4241 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |